Will the Phase 2 trial "NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC" reach primary completion on or before Aug 30, 2026?

Resolves Yes if ClinicalTrials.gov record NCT06405490 (Cancer Institute and Hospital, Chinese Academy of Medical Sciences) shows an actual primary completion date on or before Aug 30, 2026. Registered date at generation: Aug 30, 2026.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By Aug 30, 2026, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.